Weight-Loss Drugs (Ozempic, Semaglutide): Risks and Lab Tests

Ozempic, Wegovy, Mounjaro, semaglutide — in a couple of years these names have been heard from literally everywhere. Weight-loss drugs from the GLP-1 agonist group really do help reduce weight, but they are prescription medicines with real risks, not "magic shots." This article has no marketing, doses or calls to buy: let us calmly go through how they work, who they suit, what makes them risky, and which labs to monitor while taking them.

What Ozempic, Wegovy and Similar Drugs Are

The active substance of Ozempic and Wegovy is semaglutide; in Mounjaro it is tirzepatide. These are injectable drugs given usually once a week with a gradual dose increase. Semaglutide was originally created to treat type 2 diabetes, and then its weight-reducing effect came to be used in obesity too. Important: these are medicines prescribed by a doctor, not a "figure-correction" product on a whim.

How GLP-1 Agonists Work

These drugs mimic the hormone GLP-1, which the body produces after eating. They enhance insulin release in response to a rise in sugar, suppress excess glucagon, slow stomach emptying, and act on the brain's satiety centres. As a result appetite falls and a person feels full on less food. It is through these mechanisms that both the benefit (sugar control, weight loss) and part of the side effects arise.

Who They Are Prescribed For (and Who Cannot Take Them)

They are usually prescribed for type 2 diabetes and obesity (or overweight with related diseases) when lifestyle change alone is not enough. There are also important contraindications: the drugs carry a warning of risk for people with a personal or family history of medullary thyroid carcinoma and MEN 2 syndrome, require caution with pancreatic and gallbladder disease and with severe kidney disease. So the decision always rests with a doctor.

Side Effects and Risks

The most common side effects are gastrointestinal: nausea, vomiting, constipation, diarrhoea. They are dose-related and usually lessen with gradual dose increase. Less often there are more serious risks: inflammation of the pancreas (pancreatitis), gallbladder problems, dehydration and strain on the kidneys from vomiting. Large studies did not find a clear rise in thyroid cancer in people, but the label warning remains as a precaution.

Which Labs to Monitor While Taking Them

Here our field is especially useful. A sensible basic check (in agreement with a doctor) — before starting and then over time, for example at 3 and 6 months: glucose and glycated haemoglobin (HbA1c) — effect and hypoglycaemia risk; a lipid panel — fat metabolism; liver enzymes (ALT) — the liver often improves; kidney function; and TSH with caution about the thyroid. It is convenient to gather the key ones in one metabolic check-up.

Why a Doctor Matters and the Danger of "Grey" Sources

The main risk today is not the drug itself but buying "weight-loss shots" from unofficial, "grey" sources and self-dosing without supervision. This invites counterfeits, wrong dosing, no monitoring and missed contraindications. GLP-1 drugs are appropriate only on prescription and under a doctor's supervision, with baseline and follow-up labs. Weight loss "at any cost" without medical supervision is more dangerous than it seems.

This article is for informational purposes only, is not advertising or a prescription, and does not replace a doctor's consultation.